ÎÚÑ»´«Ã½

President
Robert A. Brodsky, MD, Johns Hopkins University 
Consultancy for Alexion Pharmaceuticals and Sobi Pharmaceuticals; Research funding from Alexion Pharmaceuticals; and Honoraria from Sobi Pharmaceuticals and UpToDate.

President-Elect
Mohandas Narla, DSc, New York Blood Center
Consultancy for Forma Therapeutics and New York Blood Center; Honoraria from National Institutes of Health; ÎÚÑ»´«Ã½ on a Board or Advisory Committee for Canadian Blood Services; Patents & Royalties from Lawrence Berkeley National Laboratory and UpToDate; Research Funding from National Institutes of Health.

Vice President
Belinda Avalos, MD, Atrium Health Levine Cancer Institute
ÎÚÑ»´«Ã½ on a Board or Advisory Committee for Juno CAR-T cell Advisory Board; and Patents & Royalties from BMJ Best Practice.

Secretary
Cynthia E. Dunbar, MD, National Institutes of Health
Research funding from Be Bio, Disc Medicine, and Novartis; Honoraria from UpToDate.

Treasurer
Joseph R. Mikhael, MD, FRCPC, MEd, Translational Genomics Research Institute
Honoraria from Amgen, GSK, Janssen, Karyopharm, Sanofi, and Takeda; and Consultancy for BMS and Pfizer.

Blood Editor-in-Chief
Nancy Berliner, MD, Brigham and Women's Hospital
Honoraria from UpToDate.

Blood Deputy Editor
Andrew Roberts, MBBS, PhD, Peter MacCallum Cancer Centre
ÎÚÑ»´«Ã½ on a Board or Advisory Committee for Victorian Comprehensive Cancer Centre, Australasian Leukaemia and Lymphoma Group, and Cancer Council of Victoria; Research Funding from Abbott, AbbVie, and Genentech; and Patents & Royalties from AbbVie, Genentech, and Walter and Eliza Hall Institute of Medical Research.

Blood Advances Editor-in-Chief
Catherine M. Bollard, MD, Children's National Medical Center
Equity Ownership of Caballeta Bio, Mana Therapeutics, Neximmune, and Repertoire; ÎÚÑ»´«Ã½ on a Board or Advisory Committee for Caballeta Bio, Catamaran Bio, Mana Therapeutics, and SOBI; Patents & Royalties from Mana Therapeutics; Consultancy for Neogene and Roche; and Honoraria from Neogene, Roche, and SOBI.

Blood Advances Deputy Editor
Andrew Weyrich, PhD, Oklahoma Medical Research Foundation
Indicated no conflicts of interest.

ASH Clinical News Editor-in-Chief
Aaron T. Gerds, MD, Cleveland Clinic
ÎÚÑ»´«Ã½ on a Board or Advisor Committee for AbbVie; Consultancy for CTI BioPharma, Kartos/Telios, Morphosys, Novartis, PharmaEssential, and Sierra Oncology/GSK; and Research funding from CTI BioPharma, Imago Biosciences, and Incyte.

The Hematologist Editor-in-Chief
Shaji Kumar, MD, Mayo Clinic
Consultancy for AbbVie, Amgen, Antagene, AstraZeneca, Beigene, BMS, Genentech, GSK, Oncopeptides, and Sanofi; Research funding from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Carsgen, Celgene, Genentech, Genzyme, GSK, Janssen, Millennium, Novartis, Sanofi, and Takeda; and ÎÚÑ»´«Ã½ on a Board or Advisory Committee for Janssen and Takeda.

Executive Director
Martha Liggett, ÎÚÑ»´«Ã½
Indicated no conflicts of interest.

Deputy Executive Director
Matthew Gertzog, ÎÚÑ»´«Ã½
Equity ownership of Amgen.